Oral micronized progesterone for vasomotor symptoms—a placebo-controlled randomized trial in healthy postmenopausal women
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to compare oral micronized progesterone (progesterone) with placebo as therapy for postmenopausal hot flushes and night sweats (vasomotor symptoms [VMS]). METHODS: Healthy volunteer community women 1 to 10 years since final menstruation were recruited for a randomized double-blind placebo-controlled trial of progesterone (300 mg daily at bedtime) between 2003 and 2009 and were screened for clinical, physical, or laboratory evidence of cardiovascular risks (nonsmoking, moderate body mass index [<35 kg/m], normal lipids, electrocardiogram, nondiabetic). Women recorded daily frequency and severity (1-4) of VMS in the Daily Menopause Diary during run-in (4 wk) and intervention (12 wk). Average daily VMS score (day frequency × day severity + night frequency × night severity) during final 28 therapy days was the primary outcome, analyzed by therapy, with run-in score as covariate. RESULTS: Randomized participants were 133 healthy community women with VMS, ages 44 to 62 years, with a mean (SD) VMS score of 17.0 (10.4) at run-in (VMS frequency 6.8 [3.2] episodes/d). Women were randomized to progesterone (n = 75) or placebo (n = 58); analysis included all with VMS data at run-in and on therapy (n = 68 and 46, respectively). The VMS scores of women taking progesterone were better than placebo (mean adjusted difference, -4.3 (95% CI, -6.6 to -1.9), with mean reductions of 10.0 (95% CI, -12.0 to -8.1) and 4.4 (95% CI, -6.6 to -2.2) in the progesterone and placebo arms, respectively. Discontinuation with adverse events was 9% (progesterone, 8; placebo, 4), with no serious cases. CONCLUSIONS: Oral micronized progesterone is effective for treatment of hot flushes and night sweats in healthy women early in postmenopause.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysing controlled trials with baseline and follow up measurements
Vickers, A. J., & Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7321.1123 · Cited by 2,116
Gold, E. B. (2000) · American Journal of Epidemiology · doi:10.1093/aje/152.5.463 · Cited by 861
Fournier, A., Berrino, F., & Clavel-Chapelon, F. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9523-x · Cited by 693
Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes
MacLennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002978.pub2 · Cited by 543
Commonly Used Types of Postmenopausal Estrogen for Treatment of Hot Flashes: Scientific Review
Nelson, H. D. (2004) · JAMA · doi:10.1001/jama.291.13.1610 · Cited by 296 · cited 2×
“3).5 Decreases in VMS number were similar to those in placebo-controlled trials of any HT.5,45 Estimates of our change in severity were modest and lower than those in HT trials (j0.”
ResultEfficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial
Freeman, E. W. (2011) · JAMA · doi:10.1001/jama.2010.2016 · Cited by 245
Action of progesterone on preoptic thermosensitive neurones
NAKAYAMA, T., SUZUKI, M., & ISHIZUKA, N. (1975) · Nature · doi:10.1038/258080a0 · Cited by 113
Symptoms of menopause: hot flushes
SANTORO, N. (2008) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31818093f6 · Cited by 56 · cited 1×
“Changes in lifestyle, diet, and the use of vitamin or herbal preparations improve VMS by 20 to 45 percent.(13) However, placebo- and hormone therapyYcontrolled trials of red clover and black cohosh(14) and combined herbal therapies of black cohosh and soy(15) show responses no different from those of placebo.”
BackgroundDifferent cardiovascular effects of progestins according to structure and activity
Nath, A., & Sitruk-Ware, R. (2009) · Climacteric · doi:10.1080/13697130902905757 · Cited by 46 · cited 1×
“Progesterone and synthetic progestins share common uterine effects but differ widely in molecular structure and other effects.(29,30) Medroxyprogesterone but not progesterone has been shown to increase proliferation in breast tissue in a primate model,(31) and in the E3N cohort study, there is no increased breast canc…”
BackgroundNonhormonal Therapies for Menopausal Hot Flashes: Systematic Review and Meta-analysis
Nelson, H. D., Vesco, K. K., Haney, E., Fu, R., Nedrow, A., Miller, J., Nicolaidis, C., Walker, M., & Humphrey, L. (2006) · JAMA · doi:10.1001/jama.295.17.2057 · Cited by 4
Cited by
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
“Progestogen-only formulations have been found to be effective in treating VMS,(67,68) including MPA 10 mg,(69) oral megestrol acetate 20 mg,(70) and MP 300 mg.(68) No long-term studies have”
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
“In RCTs, oral synthetic progestogens (Table 5) (174, 175) and micronized progesterone (176) were effective.”
BackgroundHormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment
Flores, V. A., Pal, L., & Manson, J. E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab011 · Cited by 174
Prior, J. C. (2020) · Drug Discovery Today: Disease Models · doi:10.1016/j.ddmod.2020.11.005 · Cited by 47
Self-citation
Metadata
- Authors
- Hitchcock, C. L., & Prior, J. C.
- Venue
- Menopause
- Published
- 2012-08
- Volume
- 19
- Issue
- 8
- Pages
- 886-893
- ISSN
- 1072-3714 (ISSN-L)
- OpenAlex
- W2146443363
- Cited by
- 110
- References
- 11
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.